SLNO
Soleno Therapeutics Inc.
$44.10
+$1.78(+4.21%)
44
Overall
55
Value
30
Tech
47
Quality
Market Cap
$2.54B
Volume
1.33M
52W Range
$37.95 - $90.32
Target Price
$112.08
Company Overview
| Mkt Cap | $2.54B | Price | $44.10 |
| Volume | 1.33M | Change | +4.21% |
| P/E Ratio | -14.5 | Open | $42.73 |
| Revenue | -- | Prev Close | $42.32 |
| Net Income | $-175.8M | 52W Range | $37.95 - $90.32 |
| Div Yield | N/A | Target | $112.08 |
| Overall | 44 | Value | 55 |
| Quality | 47 | Technical | 30 |
No chart data available
About Soleno Therapeutics Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Sector: Healthcare
Industry: Diagnostics & Research
Latest News
Analysts Offer Insights on Healthcare Companies: GE Healthcare Technologies Inc (GEHC) and Soleno Therapeutics (SLNO)
Christine Brown•7 days ago
Soleno Therapeutics Updates Executive Compensation and Severance Plans
TipRanks Auto-Generated Newsdesk•11 days ago
Soleno Therapeutics (SLNO) Receives a Buy from Wells Fargo
TipRanks Auto-Generated Intelligence Newsdesk•21 days ago
Soleno Therapeutics (SLNO) Receives a Buy from Wells Fargo
TipRanks Auto-Generated Intelligence Newsdesk•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SLNO | $44.10 | +4.2% | 1.33M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Soleno Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW